SLE Treatment During Pregnancy Study
Part of Immune system & allergy, Skin clinical trials.
This Phase 1 study looks at a treatment plan for people with systemic lupus (SLE) during pregnancy and tracks health outcomes for mother and baby. It may help doctors learn how to manage SLE safely in pregnancy and what results to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic lupus (SLE).
- You are pregnant and between ages 20 and 45.
- You can and agree to take the study medicines and attend follow-up visits during pregnancy and after delivery.
- You must be able to sign informed consent (agree to join).
- You do not have certain serious ongoing problems (heart, liver, kidney, blood, or major hormone/endocrine conditions).
- You are not allergic to prednisone, hydroxychloroquine, low-molecular-weight heparin, or aspirin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the typical pregnancy course and outcomes for women with APS or UCTD, two autoimmune-related conditions. It also checks how these conditions and treatments may affect pregnancy, so doctors can better plan care.
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.